Viridian Therapeutics Upsizes Concurrent Offerings to $350M, Finalizes Pricing for Notes and Common Stock
VRDN sits 49% above its 52-week low of $11.76 on elevated volume (3.2× avg).
Summary
Viridian Therapeutics upsized its concurrent public offerings to $350.0 million, finalizing the pricing for $225.0 million in convertible senior notes and $125.0 million in common stock.
Key Events · Financing and Capital Events · VRDN
-
Upsized Public Offering
The company increased the total gross proceeds from its concurrent offerings to $350.0 million, up from the previously announced $250.0 million, indicating strong investor demand.
-
Convertible Notes Offering Priced
The offering includes $225.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2032, with an initial conversion price of approximately $24.65 per share, a 45% premium over the common stock offering price.
-
Common Stock Offering Priced
The offering includes 7,352,942 shares of common stock priced at $17.00 per share, raising $125.0 million.
-
Use of Proceeds
Net proceeds will be used to repay outstanding debt, fund market expansion studies for the TED franchise, advance the R&D pipeline, and for general corporate purposes.
Analysis · VRDN · Life Sciences
Viridian Therapeutics has successfully upsized its concurrent public offerings, securing a substantial $350.0 million in gross proceeds, an increase from the previously announced $250.0 million. This capital raise, split between $225.0 million in convertible senior notes and $125.0 million in common stock, provides significant funding for the company. The common stock was priced at $17.00 per share, a slight discount to the last reported sale price, while the convertible notes feature an initial conversion price of $24.65, representing a notable premium of approximately 45%. The proceeds are earmarked for repaying outstanding debt, funding market expansion studies for its TED franchise, advancing its R&D pipeline, and general corporate purposes. This substantial financing follows recent positive Phase 3 data for elegrobart, providing a strong cash runway to support ongoing development and commercialization efforts, despite the potential for future dilution.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 966 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRDN was trading at $17.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $11.76 to $34.29. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.